Compare NTRB & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRB | MYO |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 63.8M |
| IPO Year | 2019 | 2017 |
| Metric | NTRB | MYO |
|---|---|---|
| Price | $5.86 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.64 |
| AVG Volume (30 Days) | 27.3K | ★ 217.8K |
| Earning Date | 12-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,036,651.00 | ★ $1,000,000,000.00 |
| Revenue This Year | $4,584.65 | $11.43 |
| Revenue Next Year | $89.09 | $12.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $2.80 | $0.61 |
| 52 Week High | $9.19 | $1.89 |
| Indicator | NTRB | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 51.43 |
| Support Level | $5.68 | $1.17 |
| Resistance Level | $6.66 | $1.75 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 31.80 | 55.29 |
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.